PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Basit Öğe Kaydı
dc.authoridON, SERCAN/0000-0003-1461-7485
dc.authoridTurker, Sema/0000-0001-9040-7266
dc.contributor.authorAvci, Okan
dc.contributor.authorIriagac, Yakup
dc.contributor.authorCavdar, Eyyuep
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorAraz, Murat
dc.contributor.authorSakalar, Teoman
dc.contributor.authorDegerli, Ezgi
dc.date.accessioned2024-10-29T17:58:27Z
dc.date.available2024-10-29T17:58:27Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (>= 65 years) with metastatic breast cancer patients were investigated.Materials and Methods: Among older patients receiving palbociclib and ribociclib, Geriatric 8 (G8) and Groningen Frailty Index were used to evaluate frailty status. Dose modifications, drug withdrawal and other serious adverse events (SAEs) were recorded and analyzed according to baseline patient characteristics.Results: A total of 160 patients from 28 centers in Turkey were included (palbociclib = 76, ribociclib = 84). Forty-three patients were >= 75 years of age. The most common cause of first dose modification was neutropenia for both drugs (97% palbociclib, 69% ribociclib). Liver function tests elevation (10%) and renal function impairment (6%) were also causes for ribociclib dose modification. Drug withdrawal rate was 3.9% for palbociclib and 6% for ribociclib. SAEs were seen in 11.8% of those taking palbociclib and 15.5% of those on riboclib. An ECOG performance status of >= 2 and being older than 75 years were associated with dose reductions. Severe neutropenia was more common in patients with non-bone-only metastatic disease, those receiving treatment third-line therapy or higher, coexistance of non-neutropenic hematological side effects (for ribociclib). Neutropenia was less common among patients with obesity.Discussion: Our results show that it can be reasonable to start palbociclib and ribociclib at reduced dose in patients aged >= 75 years and/or with an ECOG performance status >= 2.
dc.identifier.doi10.1016/j.jgo.2023.101604
dc.identifier.issn1879-4068
dc.identifier.issn1879-4076
dc.identifier.issue8en_US
dc.identifier.pmid37683369
dc.identifier.scopus2-s2.0-85169931836
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.jgo.2023.101604
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14326
dc.identifier.volume14
dc.identifier.wosWOS:001078486200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Geriatric Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGeriatrics
dc.subjectCDK 4/6 inhibitors
dc.subjectBreast cancer
dc.subjectAdverse events
dc.titlePROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu